Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 20/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.55 |
| ▸ | KDR | P35968 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4281845 | 0.90 | BRAF (0.59) | BRAFCYP2C9 | |
| SCHEMBL2855873 | 0.87 | GAA (0.53) | BRAFKDR | |
| SCHEMBL3640217 | 0.86 | BRAF (0.54) | BRAFCYP2C9KDR | |
| SCHEMBL2857455 | 0.83 | BRAF (0.68) | BRAFCYP2C9 | |
| SCHEMBL2853720 | 0.82 | BRAF (0.54) | BRAFCYP2C9 | |
| SCHEMBL3638529 | 0.80 | BRAF (0.57) | BRAFCYP2C9KDR | |
| SCHEMBL2855460 | 0.79 | CDK8 (0.45) | KDR | |
| SCHEMBL2190254 | 0.78 | BRAF (0.57) | BRAFCYP2C9KDR | |
| SCHEMBL3643117 | 0.77 | BRAF (0.57) | BRAFCYP2C9 | |
| SCHEMBL4280855 | 0.77 | MET (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2162445-B1 | HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-11-27 | — | — | EP | disclosed |
| US-8304557-B2 | Fused heterocycle derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20090163488-A1 | FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163488-A1 | FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF | NOX3, NOX5, ZYX | BRAF 1364/4885CYP2C9 1211/4885KDR 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.